Esperion Therapeutics, Inc (ESPR)

Etorro trading 970x250
Esperion Therapeutics, Inc (ESPR) Logo

About Esperion Therapeutics, Inc

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108

Esperion Therapeutics, Inc News and around…

Latest news about Esperion Therapeutics, Inc (ESPR) common stock and company :

Bitcoin Futures Arrive
19 Oct, 2021 FinancialContent

Today you can finally hold Bitcoins via an exchange-traded fund.

Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
19 Oct, 2021 Yahoo! Finance

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct, 2021 FinancialContent

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
18 Oct, 2021 FinancialContent

Esperion Therapeutics Inc's(NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to ...

Notable Monday Option Activity: ESPR, FIZZ, HFWA
18 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Esperion Therapeutics Inc (ESPR), where a total volume of 4,112 contracts has been traded thus far today, a contract volume which is representative of approximately 411,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.5% of ESPR's average daily trading volume over the past month, of 814,990 shares..

Esperion Plans Expense & Operational Structure Alignment; Shares Fall 1.5% Pre-Market
18 Oct, 2021 Yahoo! Finance

Michigan-based Esperion Therapeutics, Inc. (ESPR) plans to align its expense and operational structure to boost the growth of NEXLIZET and NEXLETOL oral medicines. The plan will also prioritize the company’s investment in the CLEAR Outcomes trial. Esperion is focused on the development and sale of oral therapies for the treatment of patients with elevated low-density lipoprotein (LDL) cholesterol. Its shares declined 1.5%, at the time of writing, in the early trade on Monday. (See Insiders’ Hot

Esperion Therapeutics to reduce workforce by 40%
18 Oct, 2021 Yahoo! Finance

Shares of Esperion Therapeutics Inc. were down 1.5% in premarket trading on Monday after the company said it plans to reduce its workforce by 40%, citing the challenges of launching two cholesterol-lowering medications during the pandemic. It also said it plans to streamline its commercial strategy, and with those programs in place, Esperion expects to save at least $20 million in 2021. Research and development expenses are now expected to be $110 to $115 million in 2021, down from previous guid

ESPERION Announces Plan for Transformative Long-Term Growth
18 Oct, 2021 Yahoo! Finance

–Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial– –Reduces overall workforce by 40 percent and further shifts marketing strategy towards a greater proportion of digital and virtual outreach– –Significant operational expense reductions expected in FY 2021 & FY 2022; estimated annualized cash savings of at least $80 million– ANN ARBOR, Mich., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Esperi

Interesting ESPR Put And Call Options For June 2022
15 Oct, 2021 FinancialContent

Investors in Esperion Therapeutics Inc (ESPR) saw new options become available this week, for the June 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

44 Biggest Movers From Yesterday
15 Oct, 2021 FinancialContent

Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. ...

More Chinese Trouble
14 Oct, 2021 FinancialContent

A day after the consumer price rise there was another price rise for producer markets.

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:REI) was changed from Neutral to Buy. For the second ...

Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
12 Oct, 2021 Yahoo! Finance

ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, November 2, 2021. Following the release, company management will host a webcast and conference call at 8:00 a.m. ET to discuss financial results and business progress. The call can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start o

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Friday's After-Market Session
24 Sep, 2021 FinancialContent

Gainers eFFECTOR Therapeutics (NASDAQ:EFTR) stock rose 4.43% to $17.91 during Friday's after-market session. The ...

How The Pieces Add Up: LABU Targets $101
16 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $101.46 per unit.

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Most Heavily Shorted Stocks
11 Sep, 2021 FinancialContent

Over the course of 2021, we have seen some aggressive short squeezes, resulting in turmoil for certain financial institutions and millions in profits for some retail traders.

A Weak Week
10 Sep, 2021 FinancialContent

Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
10 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

20 Stocks Moving in Friday's Pre-Market Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants ...

3 “Strong Buy” Stocks Flirting With a Bottom
09 Sep, 2021 Yahoo! Finance

Buying a stock at low prices would seem to be a no-brainer, the sure way to guarantee the best returns. However, most stocks that are priced low are down for a reason, and you’ll need to do your homework before buying in. Some of the reasons are generally neutral towards the quality of the company. If a firm issues a new release of shares, to raise capital, the effect may be to dilute the stock and lower the price. Or, a company may get caught up in an economic downturn, and sees its shares fall

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
09 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Consumer discretionary stocks most shorted right now: S&P Global
08 Sep, 2021 Yahoo! Finance

Short bets have risen against consumer discretionary stocks as stimulus efforts have faded, a new S&P Global Market Intelligence report found.

ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
07 Sep, 2021 FinancialContent
Oversold Conditions For Esperion Therapeutics
07 Sep, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Esperion Therapeutics (ESPR) Down 5.9% Since Last Earnings Report: Can It Rebound?
02 Sep, 2021 Yahoo! Finance

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion Therapeutics, Inc (ESPR) is a NASDAQ Common Stock listed in , ,

970x250